Sandbox: wdx: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
|-
|-
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<ref name="HerbingerSchunk2012">{{cite journal|last1=Herbinger|first1=K.-H.|last2=Schunk|first2=M.|last3=Nothdurft|first3=H. D.|last4=von Sonnenburg|first4=F.|last5=Löscher|first5=T.|last6=Bretzel|first6=G.|title=Comparative study on infection-induced thrombocytopenia among returned travellers|journal=Infection|volume=40|issue=4|year=2012|pages=373–379|issn=0300-8126|doi=10.1007/s15010-012-0242-9}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]


| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
Line 39: Line 39:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]]<ref name="EltingCantor2003">{{cite journal|last1=Elting|first1=Linda S.|last2=Cantor|first2=Scott B.|last3=Martin|first3=Charles G.|last4=Hamblin|first4=Lois|last5=Kurtin|first5=Danna|last6=Rivera|first6=Edgardo|last7=Vadhan-Raj|first7=Saroj|last8=Benjamin|first8=Robert S.|title=Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors|journal=Cancer|volume=97|issue=6|year=2003|pages=1541–1550|issn=0008-543X|doi=10.1002/cncr.11195}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
*History of [[Medication|medications]] such as:
*History of [[Medication|medications]] such as:
Line 63: Line 63:
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<ref name="Miller2003">{{cite journal|last1=Miller|first1=Penny L.|title=Heparin-induced Thrombocytopenia Recognition and Treatment|journal=AORN Journal|volume=78|issue=1|year=2003|pages=79–89|issn=00012092|doi=10.1016/S0001-2092(06)61348-3}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* [[Thrombosis]]
* [[Thrombosis]]
Line 80: Line 80:
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]]<ref name="CurtisKaliszewski2006">{{cite journal|last1=Curtis|first1=Brian R.|last2=Kaliszewski|first2=James|last3=Marques|first3=Marisa B.|last4=Saif|first4=M. Wasif|last5=Nabelle|first5=Lisle|last6=Blank|first6=Jules|last7=McFarland|first7=Janice G.|last8=Aster|first8=Richard H.|title=Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin|journal=American Journal of Hematology|volume=81|issue=3|year=2006|pages=199–201|issn=0361-8609|doi=10.1002/ajh.20516}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* History of prior [[infection]] or no history
* History of prior [[infection]] or no history
Line 96: Line 96:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<ref name="Drachman2004">{{cite journal|last1=Drachman|first1=J. G.|title=Inherited thrombocytopenia: when a low platelet count does not mean ITP|journal=Blood|volume=103|issue=2|year=2004|pages=390–398|issn=0006-4971|doi=10.1182/blood-2003-05-1742}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 112: Line 112:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]]<ref name="George2006">{{cite journal|last1=George|first1=James N.|title=Thrombotic Thrombocytopenic Purpura|journal=New England Journal of Medicine|volume=354|issue=18|year=2006|pages=1927–1935|issn=0028-4793|doi=10.1056/NEJMcp053024}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]]
| align="left" style="background:#F5F5F5;" | History of:
| align="left" style="background:#F5F5F5;" | History of:
*[[Cancer]]
*[[Cancer]]
Line 134: Line 134:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<ref name="Noris2005">{{cite journal|last1=Noris|first1=M.|title=Hemolytic Uremic Syndrome|journal=Journal of the American Society of Nephrology|volume=16|issue=4|year=2005|pages=1035–1050|issn=1046-6673|doi=10.1681/ASN.2004100861}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]
| align="left" style="background:#F5F5F5;" |History of:
| align="left" style="background:#F5F5F5;" |History of:
* [[Infections]]
* [[Infections]]
Line 151: Line 151:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Iron deficiency anemia|Iron deficiency anemia]]
Inflammatory diseases
[[Splenectomy]]
[[Essential thrombocytosis|Essential thrombocytosis]]
| align="left" style="background:#F5F5F5;" |
* Digital [[pain]]
* [[Gangrene]]
* [[Erythromelalgia]]
* H[[eadache]]
* [[Paresthesia|Paresthesias]] 
* [[Transient ischemic attack|Transient ischemic attacks]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl or ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
Line 319: Line 276:
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
Line 596: Line 569:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
|-
|-
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]<ref>{{cite journal | vauthors =  Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S |display-authors=etal | title = Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis;  |  volume = 41  | issue =  3 (41) | pages = 323–329 | date=2015}}</ref>
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |
* Sub unit A mutation disease (more common)
* Sub unit A mutation disease (more common)
Line 617: Line 590:
* The severity of factor XIII deficiency bleeds can be different in different patients  
* The severity of factor XIII deficiency bleeds can be different in different patients  
|-
|-
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid26897598">{{cite journal |vauthors=Peyvandi F, Garagiola I, Young G |title=The past and future of haemophilia: diagnosis, treatments, and its complications |journal=Lancet |volume=388 |issue=10040 |pages=187–97 |date=July 2016 |pmid=26897598 |doi=10.1016/S0140-6736(15)01123-X |url=}}</ref>
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
Line 692: Line 665:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid580488">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid19222477">{{cite journal |vauthors=Levi M, Toh CH, Thachil J, Watson HG |title=Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology |journal=Br. J. Haematol. |volume=145 |issue=1 |pages=24–33 |date=April 2009 |pmid=19222477 |doi=10.1111/j.1365-2141.2009.07600.x |url=}}</ref><ref name="pmid18066597">{{cite journal |vauthors=Ghosh K, Shetty S |title=Blood coagulation in falciparum malaria--a review |journal=Parasitol. Res. |volume=102 |issue=4 |pages=571–6 |date=March 2008 |pmid=18066597 |doi=10.1007/s00436-007-0832-0 |url=}}</ref><ref name="pmid5804882">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid1531791">{{cite journal |vauthors=Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P |title=Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies |journal=Chest |volume=101 |issue=3 |pages=816–23 |date=March 1992 |pmid=1531791 |doi= |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Trauma]]
* [[Trauma]]
Line 714: Line 687:
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid165052572">{{cite journal| author=Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG| title=Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. | journal=Arch Intern Med | year= 2006 | volume= 166 | issue= 4 | pages= 391-7 | pmid=16505257 | doi=10.1001/.391 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16505257  }}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Bleeding after trauma
* Bleeding after trauma
Line 740: Line 713:


{|
{|
|[[image:LowKECG.png|thumb|700px|center|An ECG in a person with a potassium level of 1.1 showing the classical ECG changes of ST segment depression, inverted T waves, large U waves, and a slightly prolonged PR interval. By James Heilman, MD - Own work, CC BY-SA 3.0<ref name="urlFile:LowKECG.JPG - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/w/index.php?curid=12210926 |title=File:LowKECG.JPG - Wikimedia Commons |format= |work= |accessdate=}}</ref>]]
|[[image:LowKECG.png|thumb|700px|center|An ECG in a person with a potassium level of 1.1 showing the classical ECG changes of ST segment depression, inverted T waves, large U waves, and a slightly prolonged PR interval. By James Heilman, MD - Own work, CC BY-SA 3.0]]
|}
|}
<br style="clear:left" />
<br style="clear:left" />

Revision as of 16:42, 14 December 2018

Category Subcategory Disease History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia
  • History of prior infection
+ + + + + + Nl Nl Nl
Medication-Induced Thrombocytopenia + + + + + + Nl Nl Nl Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia + + + + + + Nl Nl For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura + + + + + + Nl Nl Nl
Inherited Thrombocytopenia
  • Positive family history
+ + + + + + Nl Nl Nl
Thrombotic Thrombocytopenic Purpura History of: + + + + + + Nl Nl Nl
Hemolytic Uremic Syndrome History of: + + + + + + Nl Nl Nl
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder: + + + + Nl or ↓ Nl Nl Nl
  • AD inheritance
  • AbNlities of platelet granule formation
Acquired Disorders of Platelet Function + + + + ± ± Nl or ↓ Nl Nl Nl
Von Willebrand Disease + + + + ± ± Nl Nl See the table below for the details about different types.
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease
+ + ± Nl Nl or ↑ Nl Nl Nl
Inherited Disorders of the Vessel Wall
  • Positive family history
+ + ± Nl Nl or ↑ Nl Nl Nl
Coagulation factor disorders

[1]

Fibrinogen deficiency

Different types of the fibrinogen disorders:

+ + ± + Nl
  • Impaired fibrin cross-linking or clot dissolution
  • Mild or severe bleeding idepend on levels of functional fibrinogen
  • Variable age of onset
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Prothrombin deficiency + + + + + Nl Nl
Factor V deficiency + + + + Nl Nl
  • The severity of bleeding related to the degree of factor V deficiency
Factor VII deficiency + + + Nl Nl Nl
  • Thrombosis in inherited factor VII deficiency
  • Treatment with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
  • Easy bruising
  • Hematuria
  • Menorrhagia
  • Abortion
  • Postpartum hemorrhage
  • Epistaxis
  • Pseudotumors
  • Intracranial bleeding
  • Hemarthroses
+ + + + + Nl Nl Nl
Factor XII deficiency
  • Asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
High molecular weight kininogen (HMWK) deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Prekallikrein deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Factor XIII deficiency
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Positive family history of bleeding
± ± ± ± ± ± Nl Nl Nl or ↑ Nl Nl
  • Impaired fibrin cross-linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia Type A deficiency + + + Nl Nl Nl Nl
Type B deficiency + + + Nl Nl Nl Nl
Type C deficiency
  • Positive family history
  • Bleeding after surgery or injury
+ Rare Rare Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Rare diseases Disseminated Intravascular Coagulation + + + + + + Nl
Vitamin K Deficiency + + + + + Nl Nl or mildly prolonged Nl
An ECG in a person with a potassium level of 1.1 showing the classical ECG changes of ST segment depression, inverted T waves, large U waves, and a slightly prolonged PR interval. By James Heilman, MD - Own work, CC BY-SA 3.0


An ECG in a person with a potassium level of 1.1 showing the classical ECG changes of ST segment depression, inverted T waves, large U waves, and a slightly prolonged PR interval. By James Heilman, MD - Own work, CC BY-SA 3.0[2]


{{#ev:youtube|7TWu0_Gklzo}}

Table

Complications Polymyositis Dermatomyositis
Malignancy


  1. "File:LowKECG.JPG - Wikimedia Commons". External link in |title= (help)